Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2026 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Ian, and I will be your conference operator today.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Antipodes Partners Jacob Mitchell | 145,310 | $48,078,720 | +204% | 0.93% |
| 2. | Bronte Capital John Hempton | 37,245 | $12,323,253 | -5% | 1.22% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 25,553 | $8,454,721 | -3% | 0.06% |
| 4. | Fisher Asset Management Ken Fisher | 6,045 | $2,000,344 | 0% | |
| 5. | 681,000 | $874,375 | +10% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $333.94 | 199 | $66,454.06 | 9,443 | 2026-04-06 | Filing | |
| $331.89 | 293 | $97,243.77 | 9,642 | 2026-04-06 | Filing | |
| $330.46 | 829 | $273,951.34 | 9,935 | 2026-04-06 | Filing | |
| $329.76 | 909 | $299,751.84 | 10,764 | 2026-04-06 | Filing | |
| $320.14 | 56 | $17,927.84 | 11,673 | 2026-04-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,491,280 | $2,147,769,814 | 0.11% | |
| 2. | 5,946,706 | $1,967,586,614 | 0.05% | |
| 3. | 2,493,866 | $825,145,443 | 0.84% | |
| 4. | 934,881 | $309,324,079 | 0.07% | |
| 5. | 840,888 | $278,224,613 | 0.07% |
News See All
10 New Contenders for S&P 500 Index
Identifying new contenders for the S&P 500 has always attracted attention, as investors are constantly interested in the companies that may enter one of the most closely followed stock market benchmarks...
Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Alnylam Pharmaceuticals Inc.
8 Most Oversold Healthcare Stocks to Invest In
Calling it a textbook classic move, he stated that we had a geopolitical shock and markets sold off hard before snapping right back up, making it the classic V shape.
10 Best Growth Stocks to Buy With Highest Upside Potential
On April 9, Tom Lee, Head of Research at Fundstrat, appeared on a CNBC Television interview to discuss market conditions as the war between the US and Iran had started to cool down.
Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025
ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A copy of the letter can be downloaded here.
10 Best Future Stocks to Buy for the Next 5 Years
On March 25, Scott Chronert of Citi joined 'Closing Bell' on CNBC to discuss whether it is time to enter the market and if recent presidential actions have changed the market dynamic.
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best high growth healthcare stocks to buy now. Alnylam Pharmaceuticals Inc.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
12 Best Rebound Stocks to Buy Right Now
On March 20, oil prices rose again, shaking financial markets as prospects for a central bank interest rate cut in 2026 faded.
Hedge Fund Resource Center